Adverse Drug Reactions in Ophthalmology - are they a Myth?
DOI:
https://doi.org/10.12974/2309-6136.2013.01.01.8Keywords:
Adverse drug reactions, Pharmacovigilance, Ophthalmology, Clinical practice, Therapeutics, Toxicology, Causality assessment, World Health Organization, Systemic drugs, Ocular Therapy.Abstract
Sometimes ocular (and systemic) therapeutics may cause ocular (and systemic) diseases, namely adverse drug reactions (ADRs). The Journal of Ocular Diseases and Therapeutics is therefore doubly adequate for discussion of the theme of ADRs in Ophthalmology.
Many terms are utilized as synonyms but the correct definition of ADR (according to the World Health Organization, WHO) is: "any noxious, unintended and undesired effect of a drug, which occurs at doses used in humans for prophylaxis, diagnosis, or therapy".
Ophthalmology is one of the medical specialties in which there is a high difficulty in continuous diagnosis, assessment and treatment. Additionally, the specific and delicate anatomy and physiology of the eye may easily be disrupted by an ADR, with possible irreversible consequences. Ocular ADRs may be frequent (such as cornea verticillata caused by amiodarone) or specific. On the other hand, systemic ADRs may occur after ocular treatments (such as hypotension after instillation of a beta-blocker drop).
The timely detection and recognition of ADRs is therefore critical. Several methods exist for the detection of ADRs, but few are specific or apply to ADRs in Ophthalmology. Spontaneous reporting is a low-resource method for detection of ADRs but has flaws, namely under-detection and risk of bias. The literature can be confusing or incomplete, with several case reports and case series about ocular ADRs lacking a causality assessment (such as Naranjo's or WHO's).
In conclusion, ADRs in Ophthalmology are a heterogeneous group of ADRs that lack detection, assessment and systematization. Studies about ADRs should increase their quality for further clarification. Each ophthalmologist should know the specific ocular ADRs to systemic medication, the specific systemic ADRs to ocular medication, and to detect and treat them adequately for good clinical practice.
References
Feldman RM. Conjunctival hyperemia and the use of topical prostaglandins in glaucoma and ocular hypertension. J Ocul Pharmacol Ther 2003; 19(1): 23-35. http://dx.doi.org/10.1089/108076803762718088
Duvall, Kershner (ed). Ophthalmic medications and pharmacology. Slack Incorporated; 2nd ed. 2006; 1: 36-138.
American Academy of Ophthalmology. Ocular Pharmacology. In Fundamentals and principles in Ophthalmology. Section 2 in AAO's Basic and Clinical Science Course 2011-2012; 2: 319-417.
World Health Organization. WHO Draft Guidelines for Adverse Event Reporting and Learning Systems. 2005. Accessed from: http://www.who.int/patientsafety/events/ 05/Reporting_Guidelines.pdf. Accessed June 2013.
Johnson JA, Bootman JL. Drug-related morbidity and mortality a cost-of-illness model. Arch Intern Med 1995; 155: 1949-56. http://dx.doi.org/10.1001/archinte.1995.00430180043006
Nebeker JR, Barach P, Samore MH. Clarifying Adverse Drug Events: A Clinician’s Guide to Terminology, Documentation, and Reporting. Ann Intern Med 2004; 140: 795-801. http://dx.doi.org/10.7326/0003-4819-140-10-200405180- 00017
Leape LL, et al. Preventing adverse drug events. Am J Health Syst Pharm 1995; 52: 379-82.
World Health Organization. International Drug Monitoring: The Role of the Hospital. Geneva, Switzerland: World Health Organization; 1966. Technical Report Series No. 425. Updated in 1972.
Karch FE, Lasagna L. Adverse drug reaction- a critical review. JAMA 1975; 234: 1236-41. http://dx.doi.org/10.1001/jama.1975.03260250028021
Edwards IR, Aronson JK. ADRs: definition, diagnosis and management. Lancet 2000; 356: 1255-9. http://dx.doi.org/10.1016/S0140-6736(00)02799-9
Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 1998; 279(15): 1200-5. http://dx.doi.org/10.1001/jama.279.15.1200
Kvasz M, Allen IE, Gordon MJ, et al. Adverse drug reactions in hospitalised patients: A critique of a meta-analysis. Medscape Gen Med 2000; 2: E3.
Miguel A, Azevedo LF, Araújo M, Pereira AC. Frequency of adverse drug reactions in hospitalized patients: a systematic review and meta-analysis. Pharmacoepidemiol Drug Saf 2012; 21(11): 1139-54. http://dx.doi.org/10.1002/pds.3309
Kongkaew C, Noyce PR, Ashcroft DM. Hospital admissions associated with adverse drug reactions: a systematic review of prospective observational studies. Ann Pharmacother 2008; 42(7): 1017-25. http://dx.doi.org/10.1345/aph.1L037
Classen DC, Pestonik SL, Evans RS, Lloyd JF, Burke JP. Adverse drug events in hospitalized patients: excess length of stay, extra costs and attributable mortality. JAMA 1997; 277: 301-306. http://dx.doi.org/10.1001/jama.1997.03540280039031
Johnson JA, Bootman JL. Drug-related morbidity and mortality. Arch Intern Med 1996; 155: 1949-56. http://dx.doi.org/10.1001/archinte.1995.00430180043006
Fraunfelder FW, Fraunfelder FT. Scientific challenges in postmarketing surveillance of ocular adverse drug reactions. Am J Ophthalmol 2007; 143(1): 145-49. Epub 2006 Nov 13. http://dx.doi.org/10.1016/j.ajo.2006.10.005
Valerie Q. Wren. Ocular & Visual Side Effects Of Systemic Drugs. J Behav Optometry 2000; 11(6): 149-57.
Hollander DA, Aldave AJ. Drug-induced corneal complications. Curr Opin Ophthalmol 2004; 15(6): 541-8. http://dx.doi.org/10.1097/01.icu.0000143688.45232.15
Carelli V, Ross-Cisneros FN, Sadun AA. Optic nerve degeneration and mitochondrial dysfunction: genetic and acquired optic neuropathies. Neurochem Int 2002; 40(6): 573-84. http://dx.doi.org/10.1016/S0197-0186(01)00129-2
Abdel-Aziz S, Mamalis N. Intraoperative floppy iris syndrome. Curr Opin Ophthalmol 2009; 20(1): 37-41. http://dx.doi.org/10.1097/ICU.0b013e32831bc0ad
Cano-Parra J, Díaz-Llopis M. Drug induced uveitis. Arch Soc Esp Oftalmol 2005; 80(3): 137-49. Review. Spanish.
Miguel A, Azevedo L, Costa-Pereira A. Adverse drug reactions. In: Biotechnology Vol. 9: Diseases, Diagnostics and Therapeutics. Published by Studium Press LLC 2013; pp. 1-17.
World Health Organization. The importance of Pharmacovigilance - safety monitoring of medicinal products. 2002. Accessed from: http://apps.who.int/medicinedocs/en/d/ Js4893e/. Accessed June 2013.
Figueiras A, Herdeiro MT, Polónia J, et al. An Educational Intervention to Improve Physician Reporting of Adverse Drug Reactions: A Cluster-Randomized Controlled Trial. JAMA 2006; 296(9): 1086-93. http://dx.doi.org/10.1001/jama.296.9.1086
Miguel A, Azevedo LF, Lopes F, Freitas A, Pereira AC. Methodologies for the detection of adverse drug reactions: comparison of hospital episodes statistics databases, chart review and spontaneous reporting. Pharmacoepidemiol Drug Saf 2013; 22(1): 98-102. http://dx.doi.org/10.1002/pds.3348
Miguel A, Marques B, Freitas A, Lopes F, Azevedo L, Pereira AC. Detection of adverse drug reactions using hospital databases-a nationwide study in Portugal. Pharmacoepidemiol Drug Saf 2013. http://dx.doi.org/10.1002/pds.3468
Forster AJ, Jennings A, Chow C, Leeder C, van Walraven C. A systematic review to evaluate the accuracy of electronic adverse drug event detection. J Am Med Inform Assoc 2012; 19(1): 31-8. http://dx.doi.org/10.1136/amiajnl-2011-000454
Miguel A, Azevedo L, Silva B, Costa-Pereira A. Resource- Sparing Computerized Tool For Detection Of Adverse Drug Reactions. Int J Pharmacy Technol 2013; 5(1): 5106-28.
Tinoco A, Evans RS, Staes CJ, Lloyd JF, Rothschild JM, Haug PJ. Comparison of computerized surveillance and manual chart review for adverse events. J Am Med Inform Assoc 2011; 18(4): 491-7. http://dx.doi.org/10.1136/amiajnl-2011-000187
Fattinger K, Roos M, Veregeres P, et al. Epidemiology of drug exposure and adverse drug reactions in two Swiss departments of internal medicine. Br J Clin Pharmacol 2000; 49: 158-67. http://dx.doi.org/10.1046/j.1365-2125.2000.00132.x
Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30: 239-45. http://dx.doi.org/10.1038/clpt.1981.154
The use of the WHO–UMC system for standardized case causality assessment. Accessed from: http://www.whoumc. org/Graphics/26649.pdf. Accessed June 2013.
Rawlins MD, Thompson JW. Pathogenesis of adverse drug reactions. In: Davies DM (ed) Textbook of adverse drug reactions. Oxford University press, Oxford 1977.
Hartwig SC, Siegel J, Schneider PJ. Preventability and severity assessment in reporting adverse drug reactions. Am J Hosp Pharm 1992; 49: 2229-32.
Schumock GT, Thornton JP. Focusing on the preventability of adverse drug reactions. Hosp Pharm 1992; 27: 538.
Marmor MF. Arch Ophthalmol. Comparison of screening procedures in hydroxychloroquine toxicity 2012; 130(4): 461- 9. http://dx.doi.org/10.1001/archophthalmol.2011.371
